Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives

Folkman, 1971, Tumor angiogenesis: therapeutic implications, New England J. Med., 285, 1182, 10.1056/NEJM197111182852108 Gimbrone, 1972, Tumor dormancy in vivo by prevention of neovascularization, J. Exp. Med., 136, 261, 10.1084/jem.136.2.261 Hanahan, 1996, Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, Cell, 86, 353, 10.1016/S0092-8674(00)80108-7 Jones, 2001, Tie receptors: new modulators of angiogenic and lymphangiogenic responses, Nat. Rev. Mol. Cell Biol., 2, 257, 10.1038/35067005 Connolly, 1989, Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis, J. Clin. Invest., 54, 1470, 10.1172/JCI114322 Plate, 1992, Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo, Nature, 359, 845, 10.1038/359845a0 Cornali, 1996, Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi’s sarcoma, Am. J. Path., 149, 1851 Yoshiji, 1996, Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer, Cancer Res., 56, 2013 Aoki, 2001, Vascular endothelial growth factor/vascular permeability factor in the pathogenesis of primary effusion lymphomas, Leuk Lymphoma, 41, 229, 10.3109/10428190109057978 Plate, 1992, Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo, Nature, 359, 845, 10.1038/359845a0 Phillips, 1994, Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea, In Vivo, 8, 961 Senger, 1996, Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin, Am. J. Pathol., 149, 293 Neufeld, 1999, Vascular endothelial growth factor (VEGF) and its receptors, FASEB J., 13, 9, 10.1096/fasebj.13.1.9 Cross, 2001, FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition, Trends Pharmacol. Sci., 22, 201, 10.1016/S0165-6147(00)01676-X Benjamin, 1997, Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal, Proc. Natl. Acad. Sci. U.S.A., 94, 8761, 10.1073/pnas.94.16.8761 Stacker, 1999, A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability, J. Biol. Chem., 274, 34884, 10.1074/jbc.274.49.34884 Masood, 2001, Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors, Blood, 98, 1904, 10.1182/blood.V98.6.1904 Shweiki, 1992, Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis, Nature, 359, 843, 10.1038/359843a0 Wenger, 2000, Mammalian oxygen sensing, signalling and gene regulation, J. Exp. Biol., 203, 1253, 10.1242/jeb.203.8.1253 Nagase, 1999, Matrix metalloproteinases, J. Biol. Chem., 274, 21491, 10.1074/jbc.274.31.21491 Westermarck, 1999, Regulation of matrix metalloproteinase expression in tumor invasion, FASEB J., 13, 781, 10.1096/fasebj.13.8.781 Shapiro, 1998, Matrix metalloproteinase degradation of extracellular matrix: biological consequences, Curr. Opin. Cell Biol., 10, 602, 10.1016/S0955-0674(98)80035-5 Ray, 1995, Gelatinase A activity directly modulates melanoma cell adhesion and spreading, EMBO J., 14, 908, 10.1002/j.1460-2075.1995.tb07072.x Sternlicht, 2001, How matrix metalloproteinases regulate cell behavior, Annu. Rev. Cell Dev. Biol., 17, 463, 10.1146/annurev.cellbio.17.1.463 Meade-Tollin, 1999, Expression of multiple matrix metalloproteinases and urokinase type plasminogen activator in cultured Kaposi sarcoma cells, Acta Histochem., 101, 305, 10.1016/S0065-1281(99)80031-2 Davidson, 1999, High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma, Clin. Exp. Metastasis, 17, 799, 10.1023/A:1006723011835 Itoh, 1998, Reduced angiogenesis and tumor progression in gelatinase A-deficient mice, Cancer Res., 58, 1048 Vu, 1998, MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes, Cell, 93, 411, 10.1016/S0092-8674(00)81169-1 Rabbani, 1998, Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies, Int. J. Oncol., 12, 911 Balkwill, 2001, Inflammation and cancer: back to Virchow?, Lancet, 357, 539, 10.1016/S0140-6736(00)04046-0 Di Carlo, 2001, The intriguing role of polymorphonuclear neutrophils in antitumor reactions, Blood, 97, 339, 10.1182/blood.V97.2.339 Brigati, 2002, Tumors and inflammatory infiltrates: friends or foes?, Clin. Exp. Metastasis, 19, 247, 10.1023/A:1015587423262 Coussens, 2002, Inflammation and cancer, Nature, 420, 860, 10.1038/nature01322 Parkin, 1999, Global cancer statistics, CA Cancer J. Clin., 49, 33, 10.3322/canjclin.49.1.33 Chang, 1994, Identification of Herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma, Science, 266, 1865, 10.1126/science.7997879 Scapini, 2000, The neutrophil as a cellular source of chemokines, Immunol. Rev., 177, 195, 10.1034/j.1600-065X.2000.17706.x Addison, 2000, The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR + CXC chemokine-induced angiogenic activity, J. Immunol., 165, 5269, 10.4049/jimmunol.165.9.5269 Sgadari, 1996, Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10, Blood, 87, 3877, 10.1182/blood.V87.9.3877.bloodjournal8793877 Koch, 1992, Interleukin-8 as a macrophage-derived mediator of angiogenesis, Science, 258, 1798, 10.1126/science.1281554 Benelli, 2002, Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation, FASEB J., 16, 267, 10.1096/fj.01-0651fje Albini, 1996, The angiogenesis induced by HIV-1 Tat is mediated by the flk-1/KDR receptor on vascular endothelial cells, Nat. Med., 2, 1371, 10.1038/nm1296-1371 Albini, 1998, HIV-1 Tat protein mimicry of chemokines, Proc. Natl. Acad. Sci. U.S.A., 95, 13153, 10.1073/pnas.95.22.13153 Albini, 1996, HIV-tat protein is a heparin-binding angiogenic growth factor, Oncogene, 12, 289 Vene, 2000, HIV-Tat dependent chemotaxis and invasion, key aspects of tat mediated pathogenesis, Clin. Exp. Metastasis, 18, 533, 10.1023/A:1011991906685 O’Reilly, 1997, Endostatin: an endogenous inhibitor of angiogenesis and tumor growth, Cell, 88, 277, 10.1016/S0092-8674(00)81848-6 O’Reilly, 1994, Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma, Cell, 79, 315, 10.1016/0092-8674(94)90200-3 O’Reilly, 1996, Angiostatin induces and sustains dormancy of human primary tumors in mice, Nat. Med., 2, 689, 10.1038/nm0696-689 Griscelli, 1998, Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest, Proc. Natl. Acad. Sci. U.S.A., 95, 6367, 10.1073/pnas.95.11.6367 Feldman, 2001, Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors, J. Natl. Cancer Inst., 93, 1014, 10.1093/jnci/93.13.1014 Cornelius, 1998, Matrix metalloproteinases generate angiostatin: effects on neovascularization, J. Immunol., 161, 6845, 10.4049/jimmunol.161.12.6845 Patterson, 1997, Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9), J. Biol. Chem., 272, 28823, 10.1074/jbc.272.46.28823 Wen, 1999, The generation of endostatin is mediated by elastase, Cancer Res., 59, 6052 Scapini, 2002, Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils, J. Immunol., 168, 5798, 10.4049/jimmunol.168.11.5798 Strik, 2001, Localization of endostatin in rat and human gliomas, Cancer, 91, 1013, 10.1002/1097-0142(20010301)91:5<1013::AID-CNCR1092>3.0.CO;2-Q Hanai JJ, Dhanabal M, Karumanchi S, Albanese C, Waterman M, Chan B, et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1, J Biol Chem 2002;277(19):16464–9. Cao, 1997, Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth, J. Biol. Chem., 272, 22924, 10.1074/jbc.272.36.22924 Ji, 1998, Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis, FASEB J., 12, 1731, 10.1096/fasebj.12.15.1731 Claesson, 1998, Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD, Proc. Natl. Acad. Sci. U.S.A., 95, 5579, 10.1073/pnas.95.10.5579 Shichiri, 2001, Antiangiogenesis signals by endostatin, FASEB J., 15, 1044, 10.1096/fj.99-1083com Moser, 1999, Angiostatin binds ATP synthase on the surface of human endothelial cells, Proc. Natl. Acad. Sci. U.S.A., 96, 2811, 10.1073/pnas.96.6.2811 Jiang, 2001, Intracellular Ca(2+) signaling in endothelial cells by the angiogenesis inhibitors endostatin and angiostatin, Am. J. Physiol. Cell Physiol., 280, C1140, 10.1152/ajpcell.2001.280.5.C1140 Cao, 2000, Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients, Int. J. Mol. Med., 5, 547 Feldman, 2000, Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer, Clin Cancer Res., 6, 4628 Mannello, 2001, Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications, Apoptosis, 6, 479, 10.1023/A:1012493808790 Guedez, 2001, Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt’s lymphoma via divergent effects on tumor growth and angiogenesis, Am. J. Pathol., 158, 1207, 10.1016/S0002-9440(10)64070-9 Wojtowicz-Praga, 1997, Matrix metalloproteinase inhibitors, Invest. New Drugs, 15, 61, 10.1023/A:1005722729132 Brand, 2002, Cancer gene therapy with tissue inhibitors of metalloproteinases (TIMPs), Curr. Gene Ther., 2, 255, 10.2174/1566523024605564 Gutterman, 1994, Cytokine therapeutics: lessons from interferon alpha, Proc. Natl. Acad. Sci. U.S.A., 91, 1198, 10.1073/pnas.91.4.1198 Gohji, 1994, Human recombinant interferons-beta and -gamma decrease gelatinase production and invasion by human KG-2 renal-carcinoma cells, Int. J. Cancer, 58, 380, 10.1002/ijc.2910580313 Albini, 2000, Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach, Am. J. Pathol., 156, 1381, 10.1016/S0002-9440(10)65007-9 Giavazzi, 2001, Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors, Cancer Res., 61, 309 Tosetti, 2002, Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents, FASEB J., 16, 2, 10.1096/fj.01-0300rev Albini, 1995, Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine, Int. J. Cancer, 61, 121, 10.1002/ijc.2910610121 Cai, 1999, N-acetylcysteine inhibits endothelial cell invasion and angiogenesis, Lab. Invest., 79, 1151 Albini, 2001, Inhibition of angiogenesis-driven Kaposi’s sarcoma tumor growth in nude mice by oral N-acetylcysteine, Cancer Res., 61, 8171 Kelloff, 2000, Progress in cancer chemoprevention: development of diet-derived chemopreventive agents, J. Nutr., 130, 467S, 10.1093/jn/130.2.467S Griffiths, 1999, Certain aspects of molecular endocrinology that relate to the influence of dietary factors on the pathogenesis of prostate cancer, Eur. Urol., 35, 443, 10.1159/000019877 Jung, 2001, EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells, Br. J. Cancer., 84, 844, 10.1054/bjoc.2000.1691 Shao, 1998, Genistein exerts multiple suppressive effects on human breast carcinoma cells, Cancer Res., 58, 4851 Garbisa, 1999, Tumor invasion: molecular shears blunted by green tea, Nat. Med., 5, 1216, 10.1038/15145 Garbisa, 2001, Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate, Cancer, 91, 822, 10.1002/1097-0142(20010215)91:4<822::AID-CNCR1070>3.0.CO;2-G Dell’Aica, 2002, (-)Epigallocatechin-3-gallate directly inhibits MT1-MMP activity, leading to accumulation of non-activated MMP-2 at the cell surface, Lab. Invest., 82, 1685, 10.1097/01.LAB.0000043122.00384.91 Cao, 1999, Angiogenesis inhibited by drinking tea, Nature, 398, 381, 10.1038/18793 Sartor, 2002, (-)Epigallocatechin-3-gallate inhibits leukocyte elastase: potential of the phyto-factor in hindering inflammation, emphysema, and invasion, J. Leukoc. Biol., 71, 73, 10.1189/jlb.71.1.73 Donà M, Dell’Aica I, Calabrese F, Benelli R, Morini M, Albini A, et al. Neutrophil restraint by green tea: inhibition of inflammation and associated angiogenesis and pulmonary fibrosis. J Immunol 2003 [in press]. Lamy, 2002, Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation, Cancer Res., 62, 381 Jankun, 1997, Why drinking green tea could prevent cancer, Nature, 387, 561, 10.1038/42381 Katiyar, 1999, Prevention of UVB-induced immunosuppression in mice by the green tea polyphenol(-)-epigallocatechin-3-gallate may be associated with alterations in IL-10 and IL-12 production, Carcinogenesis, 20, 2117, 10.1093/carcin/20.11.2117 Kawamori, 1998, Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis, Cancer Res., 58, 409 Liu, 2000, Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo, J. Urol., 164, 820, 10.1097/00005392-200009010-00056 Jones, 1999, Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing, Nat. Med., 5, 1418, 10.1038/70995 Masferrer, 2000, Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors, Cancer Res., 60, 1306 Oshima, 1996, Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2(COX-2), Cell, 87, 803, 10.1016/S0092-8674(00)81988-1 De Flora, 2001, Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points, Carcinogenesis, 22, 999, 10.1093/carcin/22.7.999 Sporn, 2000, Chemoprevention of cancer, Carcinogenesis, 21, 525, 10.1093/carcin/21.3.525 Lingen, 1996, Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells, Lab. Invest., 74, 476 Lingen, 1996, Retinoic acid induces cells cultured from oral squamous cell carcinomas to become anti-angiogenic, Am. J. Pathol., 149, 247 Iurlaro, 1998, Beta interferon inhibits HIV-1 Tat-induced angiogenesis: synergism with 13-cis retinoic acid, Eur. J. Cancer, 34, 570, 10.1016/S0959-8049(97)10082-X Majewski, 1994, Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: anti-angiogenic effect on HPV-harboring tumor-cell lines, Int. J. Cancer, 57, 81, 10.1002/ijc.2910570115 Diaz, 2000, Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids, J. Biol. Chem., 275, 642, 10.1074/jbc.275.1.642 Nicholson, 1990, Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site, EMBO J., 9, 4443, 10.1002/j.1460-2075.1990.tb07895.x Schroen, 1996, Nuclear hormone receptors inhibit matrix metalloproteinase (MMP) gene expression through diverse mechanisms, Gene Exp., 6, 197 Braunhut, 1994, Retinoids modulate endothelial cell production of matrix-degrading proteases and tissue inhibitors of metalloproteinases (TIMP), J. Biol. Chem., 269, 13472, 10.1016/S0021-9258(17)36856-4 Mestre, 1997, Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells, Cancer Res., 57, 2890 Bengtson, 1999, New oral chemotherapeutic agents for lung cancer, Drugs, 58, 57, 10.2165/00003495-199958003-00009 Ribatti, 2001, Inhibition of neuroblastoma-induced angiogenesis by fenretinide, Int. J. Cancer, 94, 314, 10.1002/ijc.1441 Park, 2001, Peroxisome proliferator-activated receptors: roles in tumorigenesis and chemoprevention in human cancer, Curr. Opin. Oncol., 13, 78, 10.1097/00001622-200101000-00015 Xin, 1999, Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo, J. Biol. Chem., 274, 9116, 10.1074/jbc.274.13.9116 Bishop-Bailey, 1999, Endothelial cell apoptosis induced by peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy delta 12,14-prostaglandin J2, J. Biol. Chem., 274, 17042, 10.1074/jbc.274.24.17042 Qadan, 2000, Hepatocyte growth factor and vitamin D cooperatively inhibit androgen-unresponsive prostate cancer cell lines, Endocrinology, 141, 2567, 10.1210/en.141.7.2567 Narvaez, 2001, Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells, J. Biol. Chem., 276, 9101, 10.1074/jbc.M006876200 Mantell, 2000, 1 Alpha, 25-dihydoxyvitamin D3 inhibits angiogenesis in vitro and in vivo, Cir. Res., 87, 214, 10.1161/01.RES.87.3.214 Masood, 2000, Kaposi sarcoma is a therapeutic target for vitamin D3 receptor agonist, Blood, 96, 3188, 10.1182/blood.V96.9.3188 Goldberg, 1994, Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin, J. Biol. Chem., 269, 4355, 10.1016/S0021-9258(17)41787-X Holtmann, 1999, Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least three different cytokine- or stress-activated signal transduction pathways, Mol. Cell. Biol., 19, 6742, 10.1128/MCB.19.10.6742 Buttice, 1991, The AP-1 site is required for basal expression but is not necessary for TPA-response of the human stromelysin gene, Nucl. Acids Res., 19, 3723, 10.1093/nar/19.13.3723 Dong, 1997, Inhibition of activator protein 1 activity and neoplastic transformation by aspirin, J. Biol. Chem., 272, 9962, 10.1074/jbc.272.15.9962 Bergelson, 1994, Intracellular glutathione levels regulate fos/jun induction and activation of glutathione S-transferase gene expression, Cancer Res., 54, 36 Schule, 1991, Retinoic acid is a negative regulator of AP-1-responsive genes, Proc. Natl. Acad. Sci. U.S.A., 88, 6092, 10.1073/pnas.88.14.6092 Fanjul, 1996, 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors, J. Biol. Chem., 271, 22441, 10.1074/jbc.271.37.22441 Pages, 2000, Signaling angiogenesis via p42/p44 MAP kinase cascade, Ann. New York Acad. Sci., 902, 187, 10.1111/j.1749-6632.2000.tb06313.x Takahashi, 1999, VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells, Oncogene, 18, 2221, 10.1038/sj.onc.1202527